10 Unstoppable Stocks That Could Double Your Money

Page 9 of 9

1. Novavax Inc. (NASDAQ:NVAX)

1-Year Return: 50%

Upside Potential: 162%

Number of Hedge Fund Holders: 24

Novavax Inc. (NASDAQ:NVAX) is a clinical-stage biotechnology company. It creates novel vaccines to address various infectious diseases worldwide and employs recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to enhance immune responses.

H.C. Wainwright analyst Vernon Bernardino reaffirmed a Buy rating on Novavax (NASDAQ: NVAX) with a price target of $19, highlighting the company’s strategic shift from COVID-19 vaccine commercialisation to advancing its pipeline. The analyst emphasized Matrix-M adjuvant technology as the primary vital factor because Novavax uses this platform to negotiate lucrative agreements including its recent Sanofi joint venture that may generate $1.2 billion.

The analyst also highlighted the Phase 3 trials of the COVID-19 and influenza combination vaccine that exists within the pipeline alongside early-stage candidates focusing on RSV combinations and shingles. Operations at Novavax are expected to become profitable by 2027, and its existing cash reserves should be able to support business operations for two years. Novavax Inc. (NASDAQ:NVAX) shares have surged around 50% over the past one-year.

While we acknowledge the potential of NVAX to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NVAX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9